



Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression, and Symptoms

Laura F. Mendez Luque¹ · Amanda L. Blackmon² · Gajalakshmi Ramanathan² · Angela G. Fleischman^{1,2,3}

Published online: 22 May 2019

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Abstract

Purpose of Review Chronic inflammation is a characteristic feature of myeloproliferative neoplasm (MPN) and impacts many aspects of the disease including initiation, progression, and symptomatology.

Recent Findings The chronic inflammatory state of MPN results from disruption of immune signaling pathways leading to overproduction of inflammatory cytokines by both the neoplastic clones and bystander immune cells. This chronic inflammation may allow for the neoplastic clone to gain a selective advantage. The symptomatic burden felt by MPN patients may be a result of the chronic inflammation associated with MPN, as several cytokines have been linked with different symptoms. Pharmacologic as well as nonpharmacologic treatments of the inflammatory component of this disease may lead to decreased symptomatic burden, prevention of disease progression, and improvement in overall disease trajectory.

Summary Inflammation plays a key role in the pathogenesis of MPN and represents an important therapeutic target.

Keywords Myeloproliferative neoplasm · JAK/STAT signaling · Inflammation in cancer · Diet in cancer · Lifestyle in cancer · Inflammatory cytokines · Fatigue · Quality of life · Nonpharmacological approaches

Introduction

Inflammation plays a crucial role in the development and progression of myeloproliferative neoplasms (MPN). Myeloid malignancies are characterized by elevated levels of

inflammatory cytokines, which correlate with disease initiation and progression, symptomatic burden, and prognosis. Increased inflammatory cytokines, including tumor necrosis factor alpha (TNF- α) and interleukin-6 (IL-6), are typically observed in MPN patients [1, 2] as well as MPN mouse models [3]. These findings suggest that inflammatory cytokines are involved in the natural course of the disease and are driving the clinical manifestations.

The clinical burden of MPN develops from a combination of unrestrained production of mature myeloid cells by the neoplastic clone, and a bone marrow microenvironment of inflammatory products from activated leukocytes and platelets, which leads to the accumulation of reactive oxygen species (ROS) in the hematopoietic stem cell (HSC) compartment [4].

Role of Inflammation in MPN Disease Initiation

Inflammation may create an environment which is highly favorable for growth of the $JAK2^{V617F}$ neoplastic hematopoietic stem cells. The $JAK2^{V617F}$ mutant hematopoietic progenitors are resistant to inflammation, while $JAK2^{WT}$ cells are suppressed by inflammation, possibly through the induction of apoptosis, quiescence, or reduced self-renewal/increased differentiation of HSC [5••]. Moreover, $JAK2^{V617F}$ mutant cells themselves produce inflammatory cytokines (most notably

This article is part of the Topical Collection on *Myeloproliferative Neoplasms*

✉ Angela G. Fleischman
agf@uci.edu

Laura F. Mendez Luque
lfmendez@uci.edu

Amanda L. Blackmon
alblackm@uci.edu

Gajalakshmi Ramanathan
gramanat@uci.edu

¹ Department of Biological Chemistry, University of California Irvine, 839 Medical Sciences Rd, Sprague Hall 126, Irvine, CA 92617, USA

² Division of Hematology/Oncology, Department of Medicine, University of California Irvine, 839 Medical Sciences Rd, Sprague Hall 126, Irvine, CA 92617, USA

³ Chao Family Comprehensive Cancer Center, University of California Irvine, 839 Medical Sciences Rd, Sprague Hall 126, Irvine, CA 92617, USA

TNF- α) and also induce bystander normal cells to produce inflammatory cytokines [6••, 7••].

A chronic inflammatory state may increase one's risk of developing MPN. MPN patients are more likely to have a preceding diagnosis of autoimmune disease [8]. Interestingly, the JAK2 46/1 haplotype identified as associated with JAK2-mutated MPN is also associated with Crohn's disease [9]. Lai et al. found that MPN patient monocytes produce TNF- α for prolonged periods of time after Toll-like receptor (TLR) stimulation because they are less able to respond to the anti-inflammatory cytokine IL-10 [7••]. This defective negative regulation of TLR signaling was observed in both the mutant and wild-type cells alike from MPN patients, suggesting this is not a cell intrinsic consequence of *JAK2*^{V617F}. Moreover, the unaffected identical twin of an MPN patient was found to have prolonged TNF- α production following stimulation similar to her twin with MPN, suggesting this abnormality may be a genetic feature rather than a consequence of MPN. This work also demonstrates that the chronic inflammatory state in MPN may be due to defects in quelling inflammation after stimulation.

Aging is considered a pro-inflammatory state due to the increased release of inflammatory cytokines and immunosenescence which may likely play a role throughout myeloid malignancies. MPN is generally a disease of the elderly with the average age of onset being 65 years old, further highlighting the association between inflammation and development of MPN.

Source of Inflammation in MPN and Pathway Targets

The mechanisms driving inflammation in MPN are multifactorial and not fully understood (Fig. 1). Production of inflammatory cytokines is not exclusive to the *JAK2*^{V617F} mutant clone, demonstrating that the presence of the mutant clone creates an environment which induces bystander normal cells to produce inflammatory cytokines. Using single-cell profiling, Kleppe et al. showed that hematopoietic cells from MPN mouse models as well as primary MPN patient samples aberrantly secrete inflammatory cytokines [6••]. In addition, Stat3 was found to be critical for the production of inflammatory cytokines in MPN. Pan hematopoietic deletion of Stat3 reduced inflammatory cytokines and attenuated disease severity; however, deleting Stat3 in the MPN cells while preserving Stat3 in non-mutant cells did not reduce cytokine production nor attenuate disease pathology further supporting the key role of bystander cells as producers of inflammatory cytokines in MPN.

The ability of the mutant clone to induce inflammation may create a self-perpetuating environment for its continued selection. An inflammatory environment may be critical to the maintenance and/or expansion of the mutant clone. If so, blocking this inflammation induced by the mutant clone could be a useful therapeutic approach to potentially blunt the

expansion of mutant over wild-type cells. Blockade of mutant clone-induced inflammation would also likely have an impact on the negative consequences of the mutant clone such as accelerated atherosclerosis or potentially even thrombosis.

Derangement of JAK/STAT signaling is not the sole contributor to inflammation in MPN. Although ruxolitinib reduces inflammatory cytokines in MPN patients, it may not be enough to fully return cytokines to normal. Fisher et al. found a modest difference in pre versus post ruxolitinib plasma-level cytokines such as VEGF, TNF- α , IL-6, IL-10, and IL-16 in MF patients, demonstrating that JAK inhibition may not be sufficient to normalize inflammatory cytokines [10••].

Hyperactivation of the NF κ B signaling pathway is a key contributor to chronic inflammation in MPN. Using mass cytometry, Fisher et al. found that primary samples from myelofibrosis (MF) and secondary acute myeloid leukemia samples had constitutive NF κ B signaling and many NF κ B target genes were found to have increased expression in MF patient CD34⁺ cells. Moreover, NF κ B inhibition suppressed colony formation from MF CD34⁺ cells implicating NF κ B as a therapeutic target in MPN [11].

Yang et al. found a significant enrichment of the NF κ B signaling pathway in sorted hematopoietic stem cells from *JAK2*^{V617F} mice as compared with wild-type mice [12]. They found that the NF κ B inhibitor dimethylamino parthenolide (DMAPT) reduced proliferation of Ba/F3-EpoR-JAK2V617F cells, inhibited the growth of human *JAK2*^{V617F}-positive cell lines, and inhibited the hematopoietic progenitor colony outgrowth in *JAK2*^{V617F} mice BM and MPN patient peripheral blood CD34⁺ cells. Treatment of combination therapy with ruxolitinib and DMAPT reduced mutant myeloid precursors in the bone marrow and spleen of *JAK2*^{V617F} mice and reduced bone marrow fibrosis.


Kleppe et al. [13••] also identified activation of NF κ B in both malignant and non-malignant cells in MPN and found that inhibition of BET bromodomain proteins attenuated NF κ B signaling and reduced cytokine production in vivo. They also found that combined treatment with ruxolitinib and the BET inhibitor JQ1 reduced inflammatory cytokines, reduced disease burden, and reversed bone marrow fibrosis in mouse MPN models.

There is abundant pre-clinical evidence to support evaluation of NF κ B inhibition in MPN patients. A clinical trial is currently open at Washington University in St. Louis investigating the combination of the NF κ B inhibitor pevonedistat in combination with ruxolitinib in patients with myelofibrosis (NCT03386214).

Inflammation and Symptoms in MPN

MPN patients can experience a variety of symptoms including fatigue, sleep disturbance, night sweats, weight loss,

Fig. 1 Factors influencing inflammation in myeloproliferative neoplasms. Chronic inflammation is a multifactorial process in MPN. It is difficult to assess if it is the result from a preceding pro-inflammatory environment or if the neoplastic clone itself predisposes to its development. Understanding the different drivers of inflammation in MPN may lead to targeted treatments in the future



depression, anxiety, early satiety, pruritus, and bone pain. Fatigue is the predominant symptom, which affects 81–95% of MPN patients, and has been reported as an important distressing factor causing decreased quality of life (QoL) by cancer survivors [14–17, 18••, 19]. Fatigue in MPN not only stems from the disease itself which will be discussed below but can also be caused by cytoreductive therapies used in MPN treatment, such as hydroxyurea, anagrelide, and interferon-alpha. In MPN, a patient's QoL can also be affected by disease complications including thrombosis, hemorrhage, hepatosplenomegaly, anemia, cachexia, and weight loss [15].

Several studies have shown a correlation with inflammatory markers and perceived symptoms of disease. Elevated levels of IL-6, a highly expressed cytokine within MPNs, have been linked to cancer-related fatigue and have shown a correlation with depression (32% in a cohort of 1788 MPN patients) [20–22]. Similarly, fever and night sweats are well known to be influenced by pyrogenic cytokines (IL-1, IL-2, IL-6, TNF- α , and IFN) [23]. Clinically, Bower et al. reported a positive correlation among TNF- α levels and post-chemotherapy fatigue in women with breast cancer [24].

Abdominal symptoms are common among MPN patients and can be mostly attributed to splenomegaly, portal hypertension, mechanical obstruction, and splenic infarcts. Splenomegaly has been associated with the expansion of the malignant clone from the bone marrow microenvironment to extramedullary sites, and with specific cytokines including MIG, HGF, and IL-1RA [2].

Thrombosis, one of the principal targets of MPN therapy particularly in essential thrombocythemia (ET) and polycythemia vera (PV) patients, may result in a variety of abdominal complaints. An evaluation of 244 PV and ET patients

demonstrated a positive association between the highest CRP protein tertile and the highest rate of major thrombotic events [25]. Likewise, patients with the lowest pentraxin 3 levels were at higher risk for major thrombotic events.

Microvascular events also affect MPN patients, which can result in headaches, concentration problems, lightheadedness, dizziness, vertigo, numbness/tingling, and sexual dysfunction [26••]. Inflammation has been identified as a cause for cognitive impairment in both animal and human models. IL-6-deficient animals are protected from lipopolysaccharide (LPS)-induced cognitive impairment, suggesting that IL-6 plays a key role in interrupting the process of memory and learning [27]. In patients suffering from hematological disorders, the presence of high levels of IL-6 usually correlates with poor executive function [28].

Weight loss in MPN is complex and multifactorial. Cancer patients often suffer from cancer cachexia, a dysregulation of carbohydrate and fat metabolism in which TNF- α is responsible for the proteolysis of skeletal muscle and the enhancement of genes related to enzymes in the ubiquitin-dependent proteolytic pathway [29–32].

Pruritus has also been linked to the inflammatory cascade, which affects over 50% of the MPN population. Pruritus is predominantly observed in PV patients (65%), who have been noted to have increased number of constitutively activated and hypersensitive circulating basophils [33]. Interestingly, an increased number of mast cells was demonstrated in *Jak2*^{V617F} transgenic mice with the PV phenotype, which also may contribute to pruritus [34]. These mast cells are a source of prostaglandin, leukotriene, histamine, and tryptase, mediators of the inflammatory response involved in pruritus. Recent studies evaluating the effects of infrared thermography have

documented mast cell degranulation due to changes in temperature with the release of pyrogenic factors such as interleukins, histamine, and leukotrienes [35, 36]; this may provide some explanation for pruritus after hot showers in MPN.

Lifestyle and Environmental Influence MPN Development

Although there is a familial predisposition to acquire MPN, most cases are sporadic which suggests that lifestyle choices and environment may play an important role in MPN disease initiation. Cigarette smoking leads to a chronic inflammatory state that is the pre-stimulus for several chronic illnesses including cardiovascular disease, chronic obstructive pulmonary disease (COPD), and cancer. The association of smoking with different hematologic malignancies has been investigated and sufficient evidence indicates a role in the development of acute myeloid leukemia [37, 38]. Evidence for the role of cigarette smoking in MPN development has, until recently, been limited. Two studies of women-only cohorts found a correlation between exposure to tobacco smoke and the incidence of myeloproliferative neoplasms. The UK Million Women Study was one of the largest studies to provide sufficient power to assess tobacco smoking as a risk for subtypes of hematological malignancies and they found that current smokers had a higher risk for developing myelodysplastic syndrome (MDS) and MPN compared with never-smokers [39]. The Iowa Women's Health Study found that current cigarette smoking was associated with an increased risk of all MPNs and for the particular subtypes, there was a stronger association for PV than ET [40]. In addition, a case-control study carried out by Sørensen and Hasselbalch studied the relationship between smoking and MPN using chronic lymphoid leukemia (CLL) patients as controls and found that a history of smoking increased the odds of developing MPN compared with CLL [41]. Very recently, a Danish population-based study found smoking to be a significant risk factor for developing MPN when comparing smokers to never-smokers [42]. Also, a meta-analysis that combined several published studies reported an increased odds ratio for MPN when comparing ever-smokers to never-smokers [43]. Interestingly, the most common somatic mutation in MPN, the *JAK2*^{V617F} mutation, is more common in smokers than non-smokers, further supporting the idea that the pro-inflammatory effects of tobacco smoke induce genetic changes in hematopoietic stem cells (HSCs) [44, 45]. The positive association between a history of smoking and the risk of MPN has been postulated to occur via chronic inflammation and oxidative stress leading to genomic instability, derivation of a malignant clone, and clonal expansion in HSCs [46].

In addition to the risk for developing MPN due to smoking behavior, the effects of past or current tobacco use on MPN symptom burden are largely unknown. An internet-based

survey developed by a team of MPN investigators for MPN patients has found significant differences in symptom burden between ever-smokers and never-smokers. Of the 435 patient participants, 58% reported no history of tobacco use while 42% of the population consisted of former or current users of some form of tobacco. In terms of severity of symptom burden, current and former smokers were more likely to experience significantly higher levels of fatigue, inactivity, concentration difficulties, and decreased quality of life compared with never-smokers (personal communication, R. Scherber). While smoking behavior is gaining attention in MPN, it is also important to evaluate the molecular effects of smoking on HSCs in the MPN setting.

The human intestinal gut microbiome is increasingly appreciated for its role in metabolism and interaction with host immune cell populations. The host microbiome can also influence MPN phenotype since dysbiosis is now well-recognized to play a role in autoimmune diseases such as inflammatory bowel disease (IBD) including Crohn's disease and ulcerative colitis (UC) [47, 48], and graft-versus-host disease (GVHD) [49]. There also exists described associations between microbiota and hematopoiesis such as size of the bone marrow myeloid pool [50] steady-state hematopoiesis [51••]. Now, it has been shown that microbiota-induced differentiation of Th17 cells drives the appearance of multiple myeloma in transgenic mice and the presence of IL-17 in the bone marrow also predicted disease progression in multiple myeloma patients [52]. Interestingly, we have preliminary data indicating that the Prevotellaceae family of bacterium, as also reported by Calcinotto et al. [52], is increased in MPN patients compared with normal controls and found that the cytokines TNF-alpha and IL-17a explained the most variance in microbiome data (Fleischman lab unpublished data). Further studies with larger cohorts are required to address the causal role of microbiota in driving inflammation in MPN. Considering that the enteric microbiome plays an integral role in host immunity, there are various efforts targeting the intestinal microbial communities such as fecal microbial transplantation (FMT) [53], antibiotics and anti-fungals, and dietary interventions [54] to manage or prevent chronic inflammatory conditions.

Clonal hematopoiesis is the expansion of peripheral blood cells derived from a single HSC and has been recently reported to occur during aging [55••, 56••]. Age-related clonal hematopoiesis has been associated with adverse clinical outcomes relating to hematologic cancer, coronary heart disease, ischemic stroke, and overall mortality [55••]. Clonal hematopoiesis of indeterminate potential (CHIP) refers to mutations occurring in candidate driver genes for hematological malignancy such as DNMT3A or TET2 at a variant allele frequency greater than 2% [57]. CHIP is rare under the age of 40 but the frequency increases with age with 1 in 10 (10%) people over the age of 70 exhibiting detectable mutant peripheral blood

cells and represents precursor cells for neoplasia [55••]. Clonal hematopoiesis (CH) is very common in the elderly and is significantly associated with smoking behavior and was also found to associate with the number of mutations detected in CH [58]. Tobacco use was also associated with a higher likelihood of clonal hematopoiesis in patients with non-hematologic cancers [59••].

Ionizing radiation is a human carcinogen with an established casual role in leukemia, particularly acute myeloid leukemia in Japanese A-bomb survivors [60]. Although no direct evidence exists for increased MPN incidence following radiation exposure, it is interesting to note that MPN patients in Ukraine, exposed to the radiation from the Chernobyl nuclear accident, exhibit a different genetic profile when compared with unexposed patients. Radiation-exposed patients had a lower rate of *JAK2*^{V617F} mutation, higher rate of the type I CALR mutation, and increased number of triple-negative cases in exposed subjects when compared with unexposed MPN patients [61]. These findings indicate that MPNs acquired via exposure to ionizing radiation display distinct genomic characteristics that require further investigation.

A cluster of PV exists in Pennsylvania, which raises the question of local environmental exposure, where elevated levels of radon gas was found in indoor air and radium in the soil. In 2009, the Agency for Toxic Substances and Disease Registry (ATSDR) collected peripheral blood samples from 1170 full-time residents of Luzerne, Schuylkill, or Carbon County who had lived in the tri-county area for 1 year or longer and tested them for *JAK2*^{V617F} using a PCR-based method with a detection limit of 0.05% allele burden [62]. They found 19 (1.6%) residents who tested positive for *JAK2*^{V617F}, 14 of whom did not have a diagnosis or symptoms of MPN. In the majority of *JAK2*-positive cases without an MPN diagnosis, the *JAK2* allele burden was 1.2% or less. It is difficult to compare the prevalence of *JAK2* positivity in this area of Pennsylvania with published reports of *JAK2* screening in other populations due to differences in analytical methodologies and participant selection.

Nonpharmacological Approaches to Reduce Inflammation in MPN

Our current pharmacologic treatment of MPN often inadequately controls symptom burden and has significant side effect profiles. Traditional therapies like therapeutic phlebotomies in patients with PV [63] have been shown to be ineffective and in some cases worsen symptom burden. The *JAK1/2* inhibitor ruxolitinib reduces inflammatory cytokines and improves symptoms, but not without significant side effects such as thrombocytopenia, anemia, increased risk of skin cancer, and immunosuppression [64]. There is a crucial need to explore low-risk therapies to diminish inflammation in MPN, particularly in patients with early-stage disease, as this may

be an ideal way to reduce inflammation and empower MPN patients to change their disease trajectory (Fig. 2). Besides the minority of patients who are on interferon-alpha, little attention is placed on preventing disease progression; instead, we wait until the patient progresses to myelofibrosis and then attempt to intervene. This “watch and wait” approach can make both MPN patients and physicians alike feel powerless.

The use of exercise to combat fatigue in malignancy is an emerging field. Recently, a study found that MPN patients who were physically active reported less fatigue than those who were not [19]. Yoga has been used effectively in various conditions related to stress and inflammation, including cancer (breast, lung, pancreatic, and most recently in MPN) since it has improved the QoL by relieving stress, anxiety, depression, fatigue, and emotional and social function [65–68]. A randomized trial investigating yoga in a breast cancer cohort demonstrated a reduction in inflammatory cytokines [69].

Yoga can produce stimulating effects on physical and mental energy, and thereby could alleviate levels of fatigue in MPN patients [68, 70]. A feasibility study consisting of 38 analyzable participants [71] followed by a qualitative study with a sample size of 39 participants [72] were conducted to explore the benefits of yoga in MPN. In both studies, MPN patients were required to complete an hour of weekly yoga for 12 weeks. Preliminary data demonstrated that online yoga was a more feasible option compared with in-person yoga because many patients travel significant distances to receive specialty MPN care. Seventy-one percent (20 of 28) of patients traveled




Fig. 2 Nonpharmacologic approaches to reduce inflammation in MPN. Maintaining a healthy lifestyle may help prevent a chronic inflammatory environment in patients with strong family history of MPN and/or patients on early stages of the disease. These nonpharmacologic approaches may be able to reduce overall inflammation with the goal of reversing some of these factors or mitigating their effects

out of town and 36% (10 of 28) traveled out of state for their MPN care, suggesting that many MPN patients may not have easy access to a facility to actively engage with for in-person interventions. Furthermore, participating in online yoga may help MPN patients overcome other limitations of in-person activities, such as fatigue, pain, transportation, and scheduling difficulties [72, 73].

At the end of both trials, the research team conducted a 15- to 20-min phone interview with participants consisting of 10 questions pertaining to patients' thoughts, feelings, and perceptions of their experiences practicing online yoga. Almost all patients reported a positive impact on their physical health as a result of yoga practice. The most common mentioned benefits were increases in physical activity, reductions in fatigue, and improved sleep. Some participants reported reduced pain, easier breathing, improved circulation, improved eating habits, improvement of their MPN symptoms, or just feeling better or more health conscious in general. It was noted, however, that the primary limitations in these studies were an overrepresentation of women ($n = 34/39$) and that several participants ($n = 25/39$) had prior yoga experience. This prevents the ability to generalize the findings of the present trials to all MPN patients, and the majority of whom likely have no experience with yoga. Larger studies investigating the impact of yoga on MPN patient QoL, symptom burden, and inflammatory cytokines are forthcoming.

Diet is another nonpharmacological approach to reduce inflammation. The Mediterranean diet which is rich in fruits, vegetables, legumes, whole grains, fish, nuts, and low-fat dairy products has proven to effectively reduce CRP ($p = 0.015$) and IL-6 levels ($p = 0.025$) [74]. In addition, implementation of the Mediterranean diet has been associated with decreased incidence of various cancers such as breast, lung, and colon [75–77], suggesting that it may have some preventative effects. Low-inflammation diets have been found to induce changes in thrombotic markers with decreases in homocysteine levels ($p = 0.031$), white blood cell counts ($p = 0.001$), and fibrinogen levels ($p = 0.025$) [78].

The PREDIMED (Prevención con Dieta Mediterránea) trial was a Mediterranean diet nutritional intervention among individuals with high cardiovascular risk, but who had not yet developed a cardiovascular disease [79]. Participants were randomized into two different Mediterranean diet groups and one control group. One of the Mediterranean diet arms was given provisions of extra-virgin olive oil and the other one was given provisions of mixed nuts. Participants in both Mediterranean arms had a significantly lower incidence of major cardiovascular events (hazard ratio 0.70 for group assigned to Mediterranean diet with extra-virgin olive oil and 0.72 to the group assigned to Mediterranean diet with nuts).

Diet is an attractive tool to empower MPN patients to reduce inflammation, manage symptoms, and prevent disease

progression. In February 2017, an online survey hosted by the Mayo Clinic Survey Research Center was advertised on multiple internet websites and communities that focused on MPN [80, 81]. The purpose of this questionnaire was to collect data on demographics, MPN characteristics, nutritional habits, supplement use, and symptom burden using the MPN-10. From all over the world (37 countries), 1329 MPN patients responded to the online survey, out of which 24% were diagnosed with MF, 37% with PV, and 38% with ET. Some of the respondents (34%) reported that they were already using diet as a measure to help control their symptoms. A wide variety of sources such as books (28.2%), websites (27.1%), health care providers such as physicians, naturopaths (28.2%), online forums (23.2%), friends (12.2%), nutritionists (9.5%), phone or tablet applications (9.1%), or videos (4.2%) were used for nutritional education. About 96% of MPN patients responded that they would be willing to restrict their diet by eating only certain foods if it helped control symptom burden and the great majority, 98%, would do so if it could help stabilize or improve the course of their disease. A correlation was made between the intake of at least once per week of fast food ($p = 0.0007$), fried foods ($p = 0.0198$), pre-made snacks ($p = 0.03$), soda ($p < 0.0001$), refined sugar ($p = 0.01$), and tacos ($p = 0.03$) with worsened symptom score compared with no intake at all. Otherwise, patients who ingested at least once per week alcohol ($p < 0.0001$) and rice ($p = 0.0452$) noticed significant improvement in their symptom burden. With these last two being basic components of the Mediterranean diet, preliminary data suggests that diet may play a role in MPN symptoms and disease course.

This data provides rationale for looking at nutritional control of inflammation as a new alternative therapy to the limited interventions that have currently shown to alleviate the symptom burden of MPN patients. A feasibility trial investigating a Mediterranean diet intervention in MPN is currently open and enrolling at the University of California, Irvine. This study will determine whether MPN patients are able to adhere to a Mediterranean diet if given in-person dietician counseling and weekly written curriculum. The exploratory endpoints of this study are improvement of MPN symptom burden and reduction of plasma inflammatory cytokines.

Conclusion

There is an emerging body of evidence to support the importance of inflammation in disease pathogenesis of MPN. A combination of overproduction of inflammatory cytokines and the inability to regulate and reduce these cytokines can lead to a state of chronic inflammation which self-perpetuates the neoplastic clone. Interventions that can reduce inflammation overall or target specific cytokines may play a role in the prevention of and future treatments for MPN. Lifestyle

modification, including diet and exercise, has been associated with qualitative improvement of MPN disease burden. Future research may aim to develop measurable inflammatory markers of MPN that can help define the disease and may correlate to prognosis, phenotype, progression, and remission of disease. These markers may be used in conjunction with molecular studies, cell counts, age, and co-morbidities to risk stratify patients' disease and therefore direct treatment.

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

•• Of major importance

1. Hoermann G, Greiner G, Valent P. Cytokine regulation of microenvironmental cells in myeloproliferative neoplasms. *Mediat Inflamm*. 2015;2015:869242.
2. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. *J Clin Oncol Off J Am Soc Clin Oncol*. 2011;29(10):1356–63.
3. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. *Blood*. 2010;115(25):5232–40.
4. Hasselbalch HC. Chronic inflammation as a promoter of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? *Leuk Res*. 2013;37(2):214–20. <https://doi.org/10.1016/j.leukres.2012.10.020>.
- 5.•• Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, et al. TNF α facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. *Blood*. 2011;118(24):6392–8 **This study demonstrates that JAK2 mutant hematopoietic progenitors are resistant to inflammation and that this may allow for the emergence of JAK2 mutant cells in the context of chronic inflammation.**
- 6.•• Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. *Cancer Discov*. 2015;5(3):316–31 **This study reveals that both mutant and non-mutant cells in MPN contribute to the inflammatory state in MPN.**
- 7.•• Lai HY, Brooks SA, Craver BM, Morse SJ, Nguyen TK, Haghighi N, et al. Defective negative regulation of Toll-like receptor signaling leads to excessive TNF- α in myeloproliferative neoplasm. *Blood Adv*. 2019;3(2):122–31 **This study shows that MPN monocytes have difficulty turning off inflammatory signals and this contributes to inflammation in MPN.**
8. Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. *Haematologica*. 2010;95(7):1216–20.
9. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nat Genet*. 2008;40(8):955–62.
- 10.•• Fisher DAC, Miner CA, Engle EK, Hu H, Collins TB, Zhou A, et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK/STAT, MAP kinase, and NF κ B signaling. *Leukemia*. 2019. <https://doi.org/10.1038/s41375-019-0379-y>. **This study demonstrates that JAK inhibition is not sufficient to return cytokines to normal in MPN.**
11. Fisher DAC, Malkova O, Engle EK, Miner CA, Fulbright MC, Behbehani GK, et al. Mass cytometry analysis reveals hyperactive NF κ B signaling in myelofibrosis and secondary acute myeloid leukemia. *Leukemia*. 2017;31(9):1962–74.
12. Yang Y, Nath D, Dutta A, Crooks PA, Mohi G. The NF- κ B inhibitor DMAPT in combination with ruxolitinib displays efficacy in Jak2V617F knock-in mouse model of myeloproliferative neoplasms. *American Society of Hematology Annual Meeting*; December 1, 2018; San Diego; 2018.
- 13.•• Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. *Cancer Cell*. 2018;33(4):785–7 **This paper highlights the importance of targeting inflammation in MPN.**
14. Johansson P, Mesa R, Scherber R, Abellsson J, Samuelsson J, Birgegard G, et al. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. *Leuk Lymphoma*. 2012;53(3):441–4.
15. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. *Cancer*. 2007;109(1):68–76.
16. Mitra D, Kaye JA, Piccoro LT, Brown J, Reith K, Mughal TI, et al. Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review. *Cancer Med*. 2013;2(6):889–98.
17. Abellsson J, Andreasson B, Samuelsson J, Hultcrantz M, Ejerblad E, Johansson B, et al. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. *Leuk Lymphoma*. 2013;54(10):2226–30.
- 18.•• Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. *Blood*. 2011;118(2):401–8 **This paper describes the validation of the MPN-SAF symptom assessment form.**
19. Scherber RM, Kosiorek HE, Senyak Z, Dueck AC, Clark MM, Boxer MA, et al. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. *Cancer*. 2016;122(3):477–85.
20. Bower JE, Ganz PA, Desmond KA, Bernards C, Rowland JH, Meyerowitz BE, et al. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. *Cancer*. 2006;106(4):751–8.
21. Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. *Am J Psychiatry*. 2001;158(8):1252–7.
22. Scherber RM, Geyer HL, Mesa RA. Quality of life in MPN comes of age as a therapeutic target. *Curr Hematol Malig Rep*. 2014;9(4):324–30.

23. Kurzrock R. The role of cytokines in cancer-related fatigue. *Cancer*. 2001;92(6 Suppl):1684–8.
24. Bower JE, Ganz PA, Irwin MR, Arevalo JM, Cole SW. Fatigue and gene expression in human leukocytes: increased NF-kappaB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. *Brain Behav Immun*. 2011;25(1):147–50.
25. Barbui T. How to manage thrombosis in myeloproliferative neoplasms. *Curr Opin Oncol*. 2011;23(6):654–8.
26. Geyer HL, Dueck AC, Scherber RM, Mesa RA. Impact of inflammation on myeloproliferative neoplasm symptom development. *Mediat Inflamm*. 2015;2015:284706 **This paper correlates specific cytokines with specific symptoms in MPN.**
27. Sparkman NL, Buchanan JB, Heyen JR, Chen J, Beverly JL, Johnson RW. Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. *J Neurosci*. 2006;26(42):10709–16.
28. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. *Cancer*. 2005;104(4):788–93.
29. Tisdale MJ. Cancer cachexia: metabolic alterations and clinical manifestations. *Nutrition*. 1997;13(1):1–7.
30. Bossola M, Muscaritoli M, Costelli P, Bellantone R, Pacelli F, Busquets S, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. *Am J Physiol Regul Integr Comp Physiol*. 2001;280(5):R1518–23.
31. Ramos EJ, Suzuki S, Marks D, Inui A, Asakawa A, Meguid MM. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. *Curr Opin Clin Nutr Metab Care*. 2004;7(4):427–34.
32. Argiles JM, Busquets S, Lopez-Soriano FJ. The pivotal role of cytokines in muscle wasting during cancer. *Int J Biochem Cell Biol*. 2005;37(10):2036–46.
33. Pieri L, Bogani C, Guglielmelli P, Zingariello M, Rana RA, Bartalucci N, et al. The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. *Haematologica*. 2009;94(11):1537–45.
34. Jin X, Zhao W, Kirabo A, Park SO, Ho WT, Sayeski PP, et al. Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice. *J Immunol*. 2014;193(2):477–84.
35. Jackson N, Burt D, Crocker J, Boughton B. Skin mast cells in polycythaemia vera: relationship to the pathogenesis and treatment of pruritus. *Br J Dermatol*. 1987;116(1):21–9.
36. Wang J, Ishii T, Zhang W, Sozer S, Dai Y, Mascarenhas J, et al. Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms. *Leukemia*. 2009;23(9):1577–86.
37. Boyle P. Cancer, cigarette smoking and premature death in Europe: a review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996. *Lung Cancer*. 1997;17(1):1–60.
38. Fircanis S, Merriam P, Khan N, Castillo JJ. The relation between cigarette smoking and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological studies. *Am J Hematol*. 2014;89(8):E125–32.
39. Kroll ME, Murphy F, Pirie K, Reeves GK, Green J, Beral V. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study. *Br J Cancer*. 2012;107(5):879–87.
40. Leal AD, Thompson CA, Wang AH, Vierkant RA, Habermann TM, Ross JA, et al. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort. *Int J Cancer*. 2014;134(7):1741–50.
41. Lindholm Sorensen A, Hasselbalch HC. Smoking and Philadelphia-negative chronic myeloproliferative neoplasms. *Eur J Haematol*. 2016;97(1):63–9.
42. Pedersen KM, Bak M, Sorensen AL, Zwisler AD, Ellervik C, Larsen MK, et al. Smoking is associated with increased risk of myeloproliferative neoplasms: a general population-based cohort study. *Cancer Med*. 2018;7(11):5796–802.
43. Jayasuriya NA EC, Hasselbalch HC, Sorensen A. Cigarette smoking, complete blood count, and myeloproliferative neoplasms – a meta-analysis. *American Society of Hematology Annual Meeting*. 2017;Abstract 3199.
44. Nielsen C, Birgens HS, Nordestgaard BG, Bojesen SE. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. *Br J Haematol*. 2013;160(1):70–9.
45. Weinberg I, Borohovitz A, Krichevsky S, Perlman R, Ben-Yehuda A, Ben-Yehuda D. Janus kinase V617F mutation in cigarette smokers. *Am J Hematol*. 2012;87(1):5–8.
46. Hasselbalch HC. Smoking as a contributing factor for development of polycythemia vera and related neoplasms. *Leuk Res*. 2015;39:1137–45.
47. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci U S A*. 2008;105(43):16731–6.
48. Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, et al. Fungal microbiota dysbiosis in IBD. *Gut*. 2017;66(6):1039–48.
49. Staffas A, Burgos da Silva M, van den Brink MR. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. *Blood*. 2017;129(8):927–33.
50. Balmer ML, Schurch CM, Saito Y, Geuking MB, Li H, Cuenca M, et al. Microbiota-derived compounds drive steady-state granulopoiesis via MyD88/TICAM signaling. *J Immunol*. 2014;193(10):5273–83.
51. Josefsson KS, Baldrige MT, Kadmon CS, King KY. Antibiotics impair murine hematopoiesis by depleting the intestinal microbiota. *Blood*. 2017;129(6):729–39 **This paper demonstrates the negative effects of chronic inflammation on hematopoietic stem cells.**
52. Calcinotto A, Brevi A, Chesi M, Ferrarese R, Garcia Perez L, Grioni M, et al. Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. *Nat Commun*. 2018;9(1):4832.
53. Keshteli AH, Millan B, Madsen KL. Pretreatment with antibiotics may enhance the efficacy of fecal microbiota transplantation in ulcerative colitis: a meta-analysis. *Mucosal Immunol*. 2017;10(2):565–6.
54. Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, et al. Dietary intervention impact on gut microbial gene richness. *Nature*. 2013;500(7464):585–8.
55. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med*. 2014;371(26):2488–98 **This paper describes clonal hematopoiesis of indeterminate potential and its association with adverse clinical outcomes.**
56. Xie M, Lu C, Wang J, McLellan MD. Age-related mutations associated with clonal hematopoietic expansion and malignancies. *Nat Med*. 2014;20(12):1472–8 **This paper demonstrates that clonal hematopoiesis is common among people with cancers.**
57. Steensma DP. Clinical consequences of clonal hematopoiesis of indeterminate potential. *Blood Adv*. 2018;2(22):3404–10.
58. Zink F, Stacey SN, Norddahl GL, Frigge ML, Magnusson OT, Jonsson I, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. *Blood*. 2017;130(6):742–52.
59. Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. *Cell Stem Cell*. 2017;21(3):374–82.e4 **This paper demonstrates clonal hematopoiesis is common in people with cancer.**

60. Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. *Radiat Res.* 1994;137(2 Suppl):S68–97.
61. Poluben L, Puligandla M, Neuberger D, Bryke CR, Hsu Y, Shumeiko O, et al. Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident. *Am J Hematol.* 2019;94(1):62–73.
62. Community health screening for JAK2(V617F) mutation Luzerne, Schuylkill and Carbon Counties, Pennsylvania In: Services USDoHaH, editor. Atlanta; 2011.
63. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. *J Clin Oncol Off J Am Soc Clin Oncol.* 2011;29(6):761–70.
64. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. *N Engl J Med.* 2012;366(9):799–807.
65. Buffart LM, van Uffelen JG, Riphagen II, Brug J, van Mechelen W, Brown WJ, et al. Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials. *BMC Cancer.* 2012;12:559.
66. Cote A, Daneault S. Effect of yoga on patients with cancer: our current understanding. *Can Fam Physician.* 2012;58(9):e475–9.
67. Harder H, Parlour L, Jenkins V. Randomised controlled trials of yoga interventions for women with breast cancer: a systematic literature review. *Support Care Cancer.* 2012;20(12):3055–64.
68. Sadjja J, Mills PJ. Effects of yoga interventions on fatigue in cancer patients and survivors: a systematic review of randomized controlled trials. *Explore.* 2013;9(4):232–43.
69. Bower JE, Greendale G, Crosswell AD, Garet D, Stenlieb B, Ganz PA, et al. Yoga reduces inflammatory signaling in fatigued breast cancer survivors: a randomized controlled trial. *Psychoneuroendocrinology.* 2014;43:20–9.
70. Carson JW, Carson KM, Porter LS, Keefe FJ, Seewaldt VL. Yoga of awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial. *Support Care Cancer.* 2009;17(10):1301–9.
71. Huberty J, Eckert R, Gowin K, Mitchell J, Dueck AC, Ginos BF, et al. Feasibility study of online yoga for symptom management in patients with myeloproliferative neoplasms. *Haematologica.* 2017;102(10):e384–e8.
72. Huberty J, Eckert R, Larkey L, Gowin K, Mitchell J, Mesa R. Perceptions of myeloproliferative neoplasm patients participating in an online yoga intervention: a qualitative study. *Integr Cancer Ther.* 2018;17(4):1150–62.
73. van Waart H, van Harten WH, Buffart LM, Sonke GS, Stuijver MM, Aaronson NK. Why do patients choose (not) to participate in an exercise trial during adjuvant chemotherapy for breast cancer? *Psycho-oncology.* 2016;25(8):964–70.
74. Smidowicz A, Regula J. Effect of nutritional status and dietary patterns on human serum C-reactive protein and interleukin-6 concentrations. *Adv Nutr.* 2015;6(6):738–47.
75. Turati F, Carioli G, Bravi F, Ferraroni M, Serraino D, Montella M, et al. Mediterranean Diet and Breast Cancer Risk. *Nutrients.* 2018;10(3):326. <https://doi.org/10.3390/nu10030326>.
76. Castello A, Amiano P, Fernandez de Larrea N, Martin V, Alonso MH, Castano-Vinyals G, et al. Low adherence to the western and high adherence to the mediterranean dietary patterns could prevent colorectal cancer. *Eur J Nutr.* 2018. <https://doi.org/10.1007/s00394-018-1674-5>.
77. Schulpen M, van den Brandt PA. Adherence to the Mediterranean diet and risk of lung cancer in the Netherlands Cohort Study. *Br J Nutr.* 2018;119(6):674–84.
78. Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: the ATTICA Study. *J Am Coll Cardiol.* 2004;44(1):152–8.
79. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. *N Engl J Med.* 2018;378(25):e34.
80. Scherber RM, Langlais BT, Geyer HL, Dueck AC, Kosiorek HE, Johnston C, et al editors. Nutrition and supplement use characteristics in the myeloproliferative neoplasms: results from the Nutrient Survey. American Society of Hematology Annual Meeting; Atlanta; 2017.
81. Scherber R GH, Dueck A, Johnston C, Langlais B, Padmos L, Palmer J, Fleischman A, Mesa R. Nutritional needs and preferences of myeloproliferative neoplasm patients: phase 1A of the Nutrient Study. 22nd Congress of the European Hematology Association Madrid; 2017. p. P377.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.